Degradation of Id2 by the anaphase-promoting complex couples cell cycle exit and axonal growth by Lasorella, Anna et al.
© 2006 Nature Publishing Group 
 
Degradation of Id2 by the anaphase-promoting
complex couples cell cycle exit and axonal growth
Anna Lasorella1,2,3, Judith Stegmu¨ller5, Daniele Guardavaccaro6, Guangchao Liu1, Maria S. Carro1,
Gerson Rothschild1, Luis de la Torre-Ubieta5, Michele Pagano6, Azad Bonni5 & Antonio Iavarone1,2,4
In the developing nervous system, Id2 (inhibitor of DNA binding
2, also known as inhibitor of differentiation 2) enhances cell
proliferation, promotes tumour progression and inhibits the
activity of neurogenic basic helix–loop–helix (bHLH) transcrip-
tion factors1,2. The anaphase promoting complex/cyclosome and
its activator Cdh1 (APC/CCdh1) restrains axonal growth but the
targets of APC/CCdh1 in neurons are unknown3–5. Id2 and other
members of the Id family are very unstable proteins that are
eliminated as cells enter the quiescent state, but how they are
targeted for degradation has remained elusive6,7. Here we show
that Id2 interacts with the core subunits of APC/C and Cdh1 in
primary neurons. APC/CCdh1 targets Id2 for degradation through
a destruction box motif (D box) that is conserved in Id1 and Id4.
Depletion of Cdh1 stabilizes Id proteins in neurons, whereas Id2
D-box mutants are impaired for Cdh1 binding and remain stable
in cells that exit from the cell cycle and contain active APC/CCdh1.
Mutants of the Id2 D box enhance axonal growth in cerebellar
granule neurons in vitro and in the context of the cerebellar
cortex, and overcome the myelin inhibitory signals for growth.
Conversely, activation of bHLH transcription factors induces a
cluster of genes with potent axonal inhibitory functions including
the gene coding for the Nogo receptor, a key transducer of myelin
inhibition. Degradation of Id2 in neurons permits the accumu-
lation of the Nogo receptor, thereby linking APC/CCdh1 activity
with bHLH target genes for the inhibition of axonal growth. These
findings indicate that deregulated Id activity might be useful to
reprogramme quiescent neurons into the axonal growth mode.
To identify protein complexes of Id2 in human neuroblastoma
cells, we used immunoaffinity chromatography followed by tandem
mass spectrometry. New Id2 partners are the APC/C subunits Apc1,
Apc5 and Apc8/Cdc23 (Supplementary Fig. 1a). The identification
in vivo of complexes of Id2 and subunits of APC/C indicates that Id2
might be targeted for degradation by APC/C. The enzymatic E3
ubiquitin ligase activity of APC/C requires either the Cdc20 or Cdh1
co-activator4. Expression of Cdh1 but not that of Cdc20 led to a
marked decrease in Id2 level; this effect was prevented by proteasomal
inhibition (Fig. 1a). Moreover, Id2 was eliminated at a faster rate in
the presence of Cdh1 (Fig. 1b). Expression of Cdh1 decreased
endogenous Id2 in asynchronously growing U2OS cells without
changing the cell cycle distribution, and also in cells synchronized
in the S phase of the cell cycle with aphidicolin (Fig. 1c, d, and
Supplementary Fig. 1b, c). Activation of APC/CCdh1 also eliminated
E47-bound Id2 and destabilized Id2 carrying a deletion of the amino-
terminal 15 amino-acid residues, which have been shown to con-
tribute to Id2 ubiquitination7 (Supplementary Fig. 1d, e). Id2
associated with Cdh1 in the absence of proteasomal inhibition, but
the interaction was more efficient in cells treated with MG-132
(Supplementary Fig. 1f, g). To examine whether Id2 becomes
unstable in cells undergoing quiescence wemonitored Id2 expression
in response to serum deprivation. Id2 was downregulated and
underwent accelerated degradation in NIH 3T3 fibroblasts deprived
of serum mitogens (Supplementary Fig. 2a, b). We observed similar
results in serum-starved U2OS-Id2 and SK-N-SH neuroblastoma
cells undergoing arrest in G0/G1 after treatment with retinoic acid
(Supplementary Fig. 3a–c)8. To examine whether APC/CCdh1 regu-
lates Id2 stability in vivowe studied the levels of Id2 after a decrease in
APC/C activity through the depletion of Cdh1. Knockdown of Cdh1
by RNA interference led to elevation of the steady-state state levels of
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Figure 1 | Id2 is a substrate of APC/CCdh1. a, HeLa cells were transfected
with Id2, haemagglutinin (HA)-conjugated Cdh1 or HA–Cdc20 and treated
with N-Acetyl-L-leucyl-L-leucyl-L-norleucinal (LLnL). b, Transfected HeLa
cells were treated with cycloheximide. c, Endogenous Id2 in U2OS cells
transfected with HA–Cdh1. d, U2OS-tet-Cdh1 cells were treated with
aphidicoline before the removal of tetracycline. e, f, LAN-1 neuroblastoma
cells (e) and U2OS-Id2 cells (f) transfected with siRNA oligonucleotides.
g, LAN-1 cells were transfected with siRNA; quiescence was induced by
retinoic acid and cells were treated with cycloheximide (CHX).
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endogenous Id2 and Id1 in LAN1 neuroblastoma cells and exogenous
Id2 in U2OS cells (Fig. 1e, and Supplementary Fig. 3d). It also
prevented the downregulation of Id2 in quiescent U2OS cells and led
to a tenfold increase in the Id2 half-life in LAN1 cells undergoing cell
cycle arrest after treatment with retinoic acid (Fig. 1f, g, and
Supplementary Fig. 3e, f). However, Id3 was unchanged in Cdh1-
depleted cells (Fig. 1e). In support of a role of APC/CCdh1 in Id2
stability, expression of Emi1, a specific inhibitor of APC/C (ref. 9),
led to the accumulation of Id2 (Supplementary Fig. 3g).
We noted that Id2 contains a canonical D-boxmotif (RxxLxxxN)10
at residues 100–107, indicating that Id2 might be a direct substrate of
APC/CCdh1. The D-box motif is conserved in Id1 and Id4 but not in
Id3 (Fig. 2a). We generated mutant Id2 proteins in which the key
arginine and leucine residues were changed into glycine and valine,
respectively (Id2-DBM) and the D box was deleted (Id2dDB). Id2-
DBM and Id2dDB mutants were expressed at levels higher than
wild-type Id2 and were resistant to Cdh1-mediated destabilization
(Fig. 2b, and Supplementary Fig. 4a). Conversely, APC/CCdh1 elimi-
nated the Id2 mutant that lacks the HLH region (Id2dHLH) and also
wild-type Id1 and Id4 but not Id3 (Supplementary Fig. 4b–e). Next
we investigated whether the D box is essential for the recognition of
Id2 by APC/CCdh1. Glutathione S-transferase (GST)–Id2 but not
GST–Id2-DBM or GST–Id2dDB captured in vitro translated Cdh1
and Cdh1 from HeLa cell extract, whereas all GST–Id2 fusion
proteins captured Apc1 and Cdc27 (Fig. 2c, and Supplementary
Fig. 5a). Similarly, both Flag–Id2 and Flag–Id2-DBM associated with
APC/C core subunits, but Flag–Id2-DBM precipitated much less
Figure 2 | D-box-dependent degradation of Id proteins by APC/CCdh1.
a, Alignment of D boxes in Id proteins. b, HeLa cells were transfected with
Id2 or Id2-DBM and HA–Cdh1 and analysed by western blotting. c, Pull-
down assay with GST fusion proteins and Cdh1 and E47 translated in vitro.
d, HeLa cells were transfected with Id2 or Id2-DBM and treated with
cycloheximide (CHX). e, Quantification of Id2 (circles) and Id2-DBM
(squares) from d. f, In vitro ubiquitination assay of Id2 and Id2-DBM by
immunopurified APC/C in the presence or absence of Cdh1 translated
in vitro. Arrowheads, unmodified Id2/Id2-DBM.
Figure 3 | An APC/CCdh1–Id–bHLH pathway controls axonal growth.
a, b, Immunoprecipitation of Id2 (a) and Cdc27 (b) from CGNs. c, CGNs
transfected with siRNA oligonucleotides and analysed by western blotting.
Notch1 is the Val 1744-cleaved intracellular fragment. d, GFP (green) and
Tau (red) staining in CGNs transfected with vector and Id2-DBM. e, Axonal
length measured in CGNs transfected with vector or Id2dDB together with
GFP (n ¼ 119; asterisk, P # 0.0001). Results are means ^ s.e.m. f, CGNs
transfected with E47 and U6-CTR or U6-shCdh1 together with GFP.
g, Quantification of axonal length from f (n ¼ 300; asterisk, P # 0.001).
Results are means ^ s.e.m. h, Axonal length measured from CGNs
transfected with Id2-DBM in the absence or presence of E47 (n ¼ 76;
asterisk, P # 0.01). Results are means ^ s.e.m. i, Expression of E47 target
genes in SK-N-SH neuroblastoma cells infected with adeno-vector,
adeno-E47 and adeno-E47 plus adeno-Id2. NogoR, Nogo receptor. Results
are means ^ s.d. (n ¼ 3). j, RhoA activation assay in adenovirus-infected
SK-N-SH cells treated with Nogo-A peptide. k, SF210-E47-ER cells treated
with the indicated concentrations of 4-OHT.
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Cdh1 than Flag–Id2 (Supplementary Fig. 5b). To determine the
importance of the D-box-mediated degradation of Id2 wemonitored
the rate of degradation of Id2 and Id2-DBM. In transiently trans-
fected HeLa cells the half-life of Id2-DBM was extended more than
tenfold compared with wild-type Id2 (Fig. 2d, e). In addition,
treatment of U2OS cells with the antimitogenic cytokine transform-
ing growth factor-b efficiently depleted Id2 but did not decrease Id2-
DBM (Supplementary Fig. 5c). Accordingly, wild-type Id2 but not
Id2-DBM was polyubiquitinated in vitro by APC/C in the presence,
but not in the absence, of Cdh1 (Fig. 2f, and Supplementary Fig. 5d).
Together, these data indicate that APC/CCdh1 can polyubiquitinate
Id2 in a D-box-dependent manner. In contrast, Id2 did not affect the
integrity of the APC/C complex or impair the ability of APC/CCdh1 to
degrade other substrates (Supplementary Fig. 6).
Apart from the regulation of the cell cycle, the expression of
APC/CCdh1 in postmitotic neurons has been puzzling11. Previous
studies indicated that APC/CCdh1 directs cell-cycle-independent
functions in postmitotic neurons, including the negative control of
axonal growth. At embryonic day 16 (E16), Id2 was physically
associated with brain APC/C (Supplementary Fig. 7a). We therefore
examined whether a complex containing Id2 and APC/CCdh1 exists in
differentiated neurons, and whether APC/CCdh1 directs the degra-
dation of Id2 to control axonal growth. We found that lysates from
primary cerebellar granule neurons (CGNs) and differentiated neuro-
blastoma cells contained Id2–core APC/C and Id2–Cdh1 complexes
(Fig. 3a, b, and Supplementary Fig. 7d, e). Furthermore, postmitotic
neurons transfected with Cdh1 short interfering RNA (siRNA)
accumulated Id2, Id1 and Id4 in the absence of cell cycle re-entry
as indicated by the lack of bromodeoxyuridine incorporation,
retinoblastoma gene product phosphorylation or decrease in the
cyclin-dependent kinase inhibitor p27 (Fig. 3c, and Supplementary
Fig. 7f, g)3. Next we determined whether expression of the Id2
mutants that are resistant to APC/CCdh1-mediated degradation
stimulated axonal elongation. CGN axons are identified on the
basis of morphology, positive staining for Tau, and negative staining
for MAP-2 (refs 3, 12). In the presence of green fluorescent protein
(GFP) expression to mark transfected cells, expression of Id2-DBM
and Id2dDB but not wild-type Id2 significantly increased axonal
length in CGNs, cortical neurons and differentiated SK-N-SH cells
(Fig. 3d, e, Supplementary Figs 7h and 8a, b, and data not shown).
The same effect was evident in postnatal day 6 (P6) CGNs transfected
with Id2-DBM and cultured on top of organotypic cerebellar slices
from P9 rat pups3 (Supplementary Fig. 8c, d).
Having shown that, resembling Cdh1 silencing, the expression of
undegradable Id2 leads to unrestrained axonal growth, we investi-
gated whether restoring bHLH activity to neurons depleted of Cdh1
or expressing degradation-resistant Id2 rescues the deregulated axon
growth. As expected, knockdown of Cdh1 in CGNs promoted axonal
growth. Ectopic expression of the bHLH transcription factor E47
abolished the stimulation of axonal growth by Cdh1 knockdown and
Id2-DBM (Fig. 3f–h). These results indicate that downstream targets
of bHLH transcription factors mediate the axonal inhibitory func-
tions and activation of these targets requires the control of Id protein
accumulation by APC/CCdh1. To identify the relevant targets
recruited by the Cdh1–Id–bHLH pathway for the control of axono-
genesis, we infected SK-N-SH cells with an adenovirus expressing
E47 (Ad-E47) and determined the gene expression profile. E47
induced the expression of genes coding for inhibitors of axonal
growth including secreted molecules (Sema3F), ligands (Jagged-2)
and receptors (Nogo receptor, Unc5A, Notch1) of multiple inhibi-
tory and repellant signals for axons13–15 (Supplementary Fig. 9a).
Prominent among them, the Nogo receptor is one of the best-known
inhibitors of axonal growth on which all myelin-inhibitory signals
(Nogo-A, myelin associated glycoprotein (MAG) and oligodendro-
cytemyelin glycoprotein) converge16,17.We confirmed themicroarray
results with quantitative real time polymerase chain reaction from
cells transduced with Ad-E47 and found that coinfection with Id2
adenovirus (Ad-Id2) prevented the E47-mediated induction of anti-
axonal genes (Fig. 3i, and Supplementary Fig. 9b). The main
intracellular transducer of axonal inhibitory signals driven by Nogo
receptor is the small GTP-binding protein RhoA17. Ad-Id2 abolished
the activation of RhoA by Nogo-A inhibitory peptide (Fig. 3j). To
investigate whether bHLH transcription induces anti-axonal genes in
non-neuronal cells, we generated SF210 glioma cells expressing
conditionally active E47 fused to the ligand-binding domain of
oestrogen receptor (E47-ER). Activation of bHLH transcription by
4-hydroxytamoxifen (4-OHT) increased Nogo receptor protein and
the Val 1744-cleaved active fragment of Notch1 (Fig. 3k). Conversely,
knockdown of Cdh1 decreased E47-mediated transcriptional acti-
vation of an E-box-luciferase plasmid and inhibited the basal and
E47-induced expression of the antiaxonal signature and the Val 1744-
cleaved intracellular fragment of Notch1 (Fig. 3c, and Supplementary
Fig. 9c–e). Together, these results underscore the functional relevance
of the Cdh1–Id–bHLH pathway for axonal growth.
To evaluate the significance of deregulated Id2 in neurons whose
axonal growth had been arrested by the inhibitory myelin com-
ponents that require Nogo receptor for signalling, we transfected
CGNs plated on MAG-Fc inhibitory substrate with Id2-DBM or
empty plasmid. Id2-DBM stimulated axonal growth in the absence of
theMAG-Fc inhibitor and rescued axonal elongation in the presence of
the myelin inhibitor. Conversely, MAG-Fc markedly inhibited axonal
growth in neurons transfected with the empty plasmid (Fig. 4a, b).
Next we determined whether Id2 stability differs between neurons that
are actively growing axons and on reaching synaptogenesis when
growth is terminated. Cortical neurons undergo axonal elongation
in vitro that culminates with extensive synaptogenesis at DIV (days
Figure 4 | Significance of APC/CCdh1-mediated degradation of Id2 for
axonal growth. a, Axonal outgrowth of Id2-DBM and vector-transfected
CGNs in the presence and absence of MAG-Fc. b, Quantification of axonal
length from a. Open bars, no inhibitor; filled bars, MAG-Fc. Results are
means ^ s.e.m. (n ¼ 150; asterisk, P # 0.0001). c, Co-staining for
presynaptic synapsin-I (green) and postsynaptic PSD95 (red) in DIV 2 and
DIV 12 cortical neurons. d, Id2 expression in cortical neurons undergoing
synaptogenesis. NogoR, Nogo receptor. e, DIV 2 and DIV 12 cortical
neurons treated with cycloheximide (CHX) for the indicated durations. f,
Id2 (red) and nuclei (4,6-diamidino-2-phenylindole (DAPI), blue) staining
in DIV 2 and DIV 12 cortical neurons in the presence and absence of MG132.
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in vitro) 12 as shown by the accumulation of synaptophysin and
maturation of the postsynaptic marker PSD-95 into large clusters
juxtaposed to presynaptic synapsin-I puncta (Fig. 4c, d)18. The
steady-state levels of Id2 decreased progressively after DIV 2 and
became almost undetectable at DIV 12, when the Nogo receptor
proteinwas markedly upregulated (Fig. 4d). The reduction of the Id2
steady state between DIV 2 and DIV 12 coincided with an increased
rate of Id2 protein degradation (Fig. 4e). APC/CCdh1 inhibition by
silencing of Cdh1 led to an increase in Id1 and Id2 levels also in
cortical neurons (Supplementary Fig. 10). APC/CCdh1 activity is
localized in the nucleus19. Consistent with this notion is the obser-
vation thatMG132-mediated inhibition of the proteasome in DIV 12
neurons led to the accumulation of Id2 in the nucleus at levels
comparable to those detected at DIV 2 (Fig. 4f).
We show that APC/CCdh1 primes Id2 for degradation through a D
box as a recognition site for the Cdh1 coactivator. The activity of
Id proteins, which are invariably depleted in cells undergoing
quiescence, corresponds to the consequences of inactivation of
APC/CCdh1 in postmitotic cells. Indeed, in a manner consistent
with reactivation of the cell cycle in cells carrying inactive APC/C
(ref. 20), deregulated expression of Id2 prevents cell cycle arrest by a
wide range of antiproliferative signals21–23. Under certain experimen-
tal conditions, ectopic Id2 is able to override the quiescent state and
drive terminally differentiated cells back into the cell cycle24. The
observation that the most aggressive tumours frequently contain the
largest amounts of Id proteins raises the possibility that inactivation
of the control of Id protein stability by APC/CCdh1 might also
contribute to Id accumulation in cancer.
By setting the timing of Id protein degradation in the nervous
system, APC/CCdh1 initiates a chain of events that terminates with the
activation of downstream targets of bHLH transcription factors. The
dual activity of the brain APC/CCdh1 as an inducer of the postmitotic
state and an inhibitor of axonal growth can be viewed as an integrated
process that restrains Id proteins during distinct stages of neural
development and, as a consequence, sets the timing of bHLH-
dependent transcription. The general implication of our findings is
that neurons in active axonal growth should be viewed as relatively
‘undifferentiated’ compared with neurons that have reached their
targets and are unable to resume neurite outgrowth. We suggest that,
by disabling the APC/CCdh1–Id–bHLH axis, degradation-resistant
forms of Id proteins might provide beneficial effects for axonal
regeneration of damaged neurons.
METHODS
Transfections and siRNA. Cell transfection was performed with Lipofectamine
2000 (Invitrogen). CGNs, cortical neurons and SK-N-SH cells differentiated
with retinoic acid and brain-derived neurotrophic factor25 were transfected three
times with 100 nM siRNA oligonucleotides and the Gene Silencer siRNA








GUAAACUUC-3 0 , 5 0 -CGCCAGAGCUUCAGGACGA-3 0 , 5 0 -AAGGGUCUCU
UUACGUAUU-3 0 ) and U6shCdh1 (5 0 -GGCUUCGUGCAGAUCUGGGAA-3 0 ).
Lamin and firefly luciferase Smart Pools (Dharmacon) served as negative controls.
RhoA assay. SK-N-SH cells were infected with Ad-vector or Ad-Id2 at a
multiplicity of infection of 50. After 24 h, cells were stimulated by the addition
of the Nogo-A peptide Nogo-P4 (8mM;Alpha Diagnostic) for 30min. GTP-RhoA
was precipitated by using beads with GST–Rho-binding domain (RBD) of
rhotekin, and detected with anti-RhoA antibodies in accordance with the
manufacturer’s guidelines (Cytoskeleton). Additional methods are described
in Supplementary Information.
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